Power Law company profile

Oculis

Biotech & Life Sciences · Saint-Sulpice, Switzerland · Founded 2017 Unicorn

Development of non-invasive topical treatment for back-of-the-eye diseases

Valuation

$1.33B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

13 investors on Oculis's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Brunnur Ventures

Silfurberg

Series B+ 11 investors entered at this stage

Silfurberg

Earlybird Venture Capital

VI Partners

Pivotal Life Sciences

Nan Fung Life Sciences Real Estate

Tekla Capital Management

Wille AG

BVCF

Novartis Venture Fund

Bay City Capital

Hyfinity Investments

Global footprint

Where Oculis has talent and traffic

Workforce by country

🇨🇭 Switzerland · Saint-Sulpice HQ

Book a demo for the full country breakdown

Web traffic by country

13K monthly visits
across markets

🇺🇸 United States34.6%

🇮🇸 Iceland21.5%

🇨🇭 Switzerland13.8%

🇬🇧 United Kingdom13.1%

🇮🇳 India12.3%

Top 5 markets shown

Market sentiment

What the market is saying about Oculis

An AI-synthesized read of the highest-engagement posts about Oculis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Oculis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles